Uncategorized

  • July 10, 2025

Brenig Therapeutics Announces Appointments of David L. Lucchino as CEO and Tien Dam, M.D., as Chief Medical Officer, Expands Pipeline

Acquires a highly selective and brain penetrant NLRP3 inhibitor from Mwyngil Therapeutics Company’s lead candidate BT-267, a potential best-in-class LRRK2 inhibitor for the treatment for Parkinson’s disease, continues advancing in the clinic Somerville, MA – July 10, 2025 – Brenig Therapeutics, a clinical-stage biotechnology company pioneering AI-powered small-molecule therapies for neurodegenerative diseases, today announced two […]
Read more
  • November 26, 2024

Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson’s Disease

Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and LRRK2-associated Parkinson’s disease. Advancement of Brenig’s clinical program is supported by a recent $65 million financing round, led by New Enterprise Associates. The trial began in November 2024, dosing healthy […]
Read more
  • July 23, 2024

Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson’s Disease Pipeline

NEA led the round with significant participation from existing and new investors Brenig Therapeutics Inc. (Brenig), a pioneering neurology-focused drug development company utilizing an AI/ML-based discovery platform, today announced the closing of a $65 million Series A financing. The financing was led by New Enterprise Associates (NEA) with support from an additional US-based healthcare investor […]
Read more
  • March 18, 2024

Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson’s Disease at the ACS Spring 2024 Conference

Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024. Brenig’s innovative approach to the rationally […]
Read more
  • December 4, 2023

Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson’s Disease Conference

Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, announces new data on its LRRK2 inhibitor drug candidate, BT-0267. The results were unveiled at the prestigious Future of Parkinson’s Disease Conference. LRRK2, recognized as a crucial drug target in Parkinson’s disease, plays a major role in the pathogenesis of the […]
Read more